← Back to Search

Amino Acid

Glutamine for Indigestion

Phase 1 & 2

Recruiting

Led By David Cangemi, MD

Research Sponsored by David J. Cangemi

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 weeks

Awards & highlights

Study Summary

This trial looks at how glutamine affects patients with functional dyspepsia, comparing it with a placebo. It looks at safety & treatment results.

Who is the study for?

This trial is for people in good health with functional dyspepsia, which causes indigestion. They must fit the Rome IV criteria for this condition and can't have allergies to certain sugars, liver or kidney problems, be pregnant or breastfeeding, use tobacco heavily, drink excessively, or have had recent stomach surgery.Check my eligibility

What is being tested?

Researchers are testing if glutamine—an amino acid that fuels intestinal cells—can improve symptoms of functional dyspepsia compared to a placebo. The study will measure safety and effectiveness by observing changes in intestinal permeability.See study design

What are the potential side effects?

While not explicitly listed here, potential side effects may include digestive discomfort since glutamine affects gut function. However, as an amino acid naturally present in the body, it's generally considered safe at recommended doses.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Adverse Events

Change in Functional Dyspepsia symptoms

Change in symptoms of bloating

+1 more

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Glutamine GroupActive Control1 Intervention

Subjects will receive glutamine for 28 days.

Group II: Placebo GroupPlacebo Group1 Intervention

Subjects will receive placebo for 28 days.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

David J. CangemiLead Sponsor

David Cangemi, MDPrincipal InvestigatorMayo Clinic

1 Previous Clinical Trials

Media Library

Glutamine (Amino Acid) Clinical Trial Eligibility Overview. Trial Name: NCT05655819 — Phase 1 & 2

Indigestion Clinical Trial 2023: Glutamine Highlights & Side Effects. Trial Name: NCT05655819 — Phase 1 & 2

Glutamine (Amino Acid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05655819 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can adults over 20 years old participate in this medical trial?

"Applicants aged from 18 to 75 are eligible for this trial, while 5 and 21 other trials specifically cater towards minors and seniors respectively."

Answered by AI

Are there any opportunities for individuals to volunteer in this experiment?

"As per the information hosted on clinicaltrials.gov, this study is not presently enrolling patients. The trial was initially published on January 1st 2023 and had its last update on December 9th 2022. Despite this, there are 27 other medical trials actively searching for eligible individuals at present."

Answered by AI

What demographic is best suited to join this medical study?

"This medical research is seeking 30 individuals between 18 and 75 who currently suffer from functional dyspepsia. For eligibility, the Rome IV criteria must be met (https://theromefoundation.org/rome-iv/rome-iv-criteria/) and patients should generally demonstrate good health at initial evaluation. Based on symptoms assessment, participants will then be categorized into either PDS, EPS or mixed subtype of FD."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of Glutamine to Treat Intestinal Permeability in Functional Dyspepsia

David J. Cangemi 2023. "A Study of Glutamine to Treat Intestinal Permeability in Functional Dyspepsia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05655819.

All > Dyspepsia